Annovis Bio (NYSE:ANVS) reported its full-year 2025 financial results and clinical milestones on March 16, 2026, highlighting a period of aggressive execution for its neurodegenerative disease pipeline.
Nasus Pharma (NYSE:NSRX) announced positive topline results from its Phase 2 clinical study of NS002, a proprietary intranasal epinephrine powder designed to treat life-threatening allergic reactions.
Nebius (NASDAQ:NBIS) shares surged 13% to $128.08 in premarket trading on Monday following the announcement of a landmark five-year agreement with Meta Platforms (NASDAQ:META).
Agenus (NASDAQ:AGEN) reported its financial results for the fourth quarter and full year ended December 31, 2025, marking a transition from a purely clinical-stage company to one generating initial pre-commercial revenue.
Bitdeer Technologies Group (NASDAQ:BTDR) released its unaudited mining and operations update for February 2026, highlighting its position as a dominant force in the global digital asset and AI infrastructure landscape.
Meta Platforms (NASDAQ:META) shares rose 3% in premarket trading on Monday following reports that the company is considering laying off at least 20% of its workforce.
Tilray Brands (NASDAQ:TLRY) on Monday announced it has entered into an asset purchase agreement to acquire key BrewDog operating assets in the United States, including the Columbus, Ohio brewery, three Ohio pubs, a Columbus hotel, the Las Vegas flagship brewpub, a franchised Denver location and a licensed site at Columbus airport.
CytomX Therapeutics (NASDAQ:CTMX) reported its full-year 2025 financial results and a strategic business update on March 16, 2026, highlighting the continued evolution of its Probody® platform.
Science Applications International Corp. (NASDAQ:SAIC) reported its fiscal fourth quarter and full-year 2026 results on March 16, 2026, showcasing a company in the midst of a significant structural and leadership transition.
OPAL Fuels (NASDAQ:OPAL) announced its fourth-quarter and full-year 2025 financial results on Monday, highlighting a year of robust operational growth and strategic capital management.
WW International (NASDAQ:WW) reported its fourth-quarter and full-year 2025 results on March 16, 2026, signaling a successful stabilization of its business model following a major financial restructuring mid-year.
Eli Lilly and Company (NYSE:LLY) on Monday announced positive topline results from the Phase 3 ADorable-1 trial evaluating EBGLYSS (lebrikizumab-lbkz) in patients aged six months to 18 years with moderate-to-severe atopic dermatitis.
